JP2017512794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512794A5 JP2017512794A5 JP2016559249A JP2016559249A JP2017512794A5 JP 2017512794 A5 JP2017512794 A5 JP 2017512794A5 JP 2016559249 A JP2016559249 A JP 2016559249A JP 2016559249 A JP2016559249 A JP 2016559249A JP 2017512794 A5 JP2017512794 A5 JP 2017512794A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- trifluoromethyl
- benzamide
- pyrazole
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 tetrahydronaphthyridinyl Chemical group 0.000 claims 346
- 125000000623 heterocyclic group Chemical group 0.000 claims 39
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 150000002431 hydrogen Chemical group 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 4
- 229940053128 nerve growth factor Drugs 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- PAMCRRDMORMCSM-UHFFFAOYSA-N n-(trifluoromethyl)benzamide Chemical compound FC(F)(F)NC(=O)C1=CC=CC=C1 PAMCRRDMORMCSM-UHFFFAOYSA-N 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012305 Demyelination Diseases 0.000 claims 2
- 206010067601 Dysmyelination Diseases 0.000 claims 2
- IOORZMBILFXYQY-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)CC(=O)O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)CC(=O)O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C IOORZMBILFXYQY-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 101150111783 NTRK1 gene Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- NDGNKOKRFUFATL-UHFFFAOYSA-N 6-[5-[[2-fluoro-5-(1H-pyrazol-5-yl)-4-(trifluoromethyl)benzoyl]amino]-6-phenylpyridin-3-yl]-N-methylpyridine-3-carboxamide Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=C2)C(=O)NC)C=C(C(=C1)C(F)(F)F)C1=NNC=C1 NDGNKOKRFUFATL-UHFFFAOYSA-N 0.000 claims 1
- GNBROKXSIMUYMP-UHFFFAOYSA-N C(C)(=O)N1CC=2C=C(C(=NC2CC1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O Chemical compound C(C)(=O)N1CC=2C=C(C(=NC2CC1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O GNBROKXSIMUYMP-UHFFFAOYSA-N 0.000 claims 1
- AEAGEILBJIDBFR-UHFFFAOYSA-N C(C)(=O)NCC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NNC=C1)C(F)(F)F)F)=O Chemical compound C(C)(=O)NCC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NNC=C1)C(F)(F)F)F)=O AEAGEILBJIDBFR-UHFFFAOYSA-N 0.000 claims 1
- FVJAUCAVHYAINU-UHFFFAOYSA-N C(C)(=O)NCC=1C=NC(=NC=1)C=1C=C(C(=NC=1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O Chemical compound C(C)(=O)NCC=1C=NC(=NC=1)C=1C=C(C(=NC=1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O FVJAUCAVHYAINU-UHFFFAOYSA-N 0.000 claims 1
- JHJRTSFXFZTQBX-UHFFFAOYSA-N CC(=O)N1CCC2=NC(=C(NC(=O)C3=CC(C4=NC=CC=N4)=C(C=C3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 Chemical compound CC(=O)N1CCC2=NC(=C(NC(=O)C3=CC(C4=NC=CC=N4)=C(C=C3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 JHJRTSFXFZTQBX-UHFFFAOYSA-N 0.000 claims 1
- PSZAYWQTGPVGTP-UHFFFAOYSA-N CN1C=CC(=N1)C1=C(C=CC(=C1)C(=O)NC1=C(N=C2CCN(CC(O)=O)CC2=C1)C1=CC=CC=C1)C(F)(F)F Chemical compound CN1C=CC(=N1)C1=C(C=CC(=C1)C(=O)NC1=C(N=C2CCN(CC(O)=O)CC2=C1)C1=CC=CC=C1)C(F)(F)F PSZAYWQTGPVGTP-UHFFFAOYSA-N 0.000 claims 1
- XXAZNUDCXFTURA-UHFFFAOYSA-N CN1C=CC(=N1)C1=CC(C(=O)NC2=C(N=C3CCN(CC3=C2)C(N)=O)C2=CC=CC=C2)=C(F)C=C1C(F)(F)F Chemical compound CN1C=CC(=N1)C1=CC(C(=O)NC2=C(N=C3CCN(CC3=C2)C(N)=O)C2=CC=CC=C2)=C(F)C=C1C(F)(F)F XXAZNUDCXFTURA-UHFFFAOYSA-N 0.000 claims 1
- ATLNHWLHOWOCPK-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1C=C(C=NC1C1=CC=CC=C1)C(=O)N Chemical compound CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1C=C(C=NC1C1=CC=CC=C1)C(=O)N ATLNHWLHOWOCPK-UHFFFAOYSA-N 0.000 claims 1
- YRZMKDCYKMJIOW-UHFFFAOYSA-N CNC(=O)N1CCC2=NC(=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 Chemical compound CNC(=O)N1CCC2=NC(=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 YRZMKDCYKMJIOW-UHFFFAOYSA-N 0.000 claims 1
- ARQMJVYNILTACL-UHFFFAOYSA-N CS(=O)(=O)N1CCC2=NC(=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 Chemical compound CS(=O)(=O)N1CCC2=NC(=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 ARQMJVYNILTACL-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- RJWTUKDPJFFNLD-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)C(C(=O)O)(C)C)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)C(C(=O)O)(C)C)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C RJWTUKDPJFFNLD-UHFFFAOYSA-N 0.000 claims 1
- NDKZGTKXNHDWAO-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)C)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)C)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 NDKZGTKXNHDWAO-UHFFFAOYSA-N 0.000 claims 1
- ZANJVJFOGFOABD-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)C)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1OC(CC1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)C)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1OC(CC1)C ZANJVJFOGFOABD-UHFFFAOYSA-N 0.000 claims 1
- LBNDRHGWPOXBLZ-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)C)C2=CC=CC=C2)C=CC(=C1F)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)C)C2=CC=CC=C2)C=CC(=C1F)C LBNDRHGWPOXBLZ-UHFFFAOYSA-N 0.000 claims 1
- WSEWGTPRJVCSCN-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)CN2C(CCCC2)=O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)CN2C(CCCC2)=O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C WSEWGTPRJVCSCN-UHFFFAOYSA-N 0.000 claims 1
- KAHBJSTXGJGOJC-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)CN2C(NCC2)=O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)CN2C(NCC2)=O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C KAHBJSTXGJGOJC-UHFFFAOYSA-N 0.000 claims 1
- NQENVZQSBBRBTK-QHCPKHFHSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)CNC(=O)[C@H]2NCCOC2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)CNC(=O)[C@H]2NCCOC2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C NQENVZQSBBRBTK-QHCPKHFHSA-N 0.000 claims 1
- DRBLJQCLFSZGHS-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)CNC(CO)=O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)CNC(CO)=O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C DRBLJQCLFSZGHS-UHFFFAOYSA-N 0.000 claims 1
- QSTKCWODVOZGLR-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC=3CN(CCC=3C=2)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC=3CN(CCC=3C=2)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C QSTKCWODVOZGLR-UHFFFAOYSA-N 0.000 claims 1
- TUVKHJJOKKVQQH-HNNXBMFYSA-N FC1=C(C(=O)NC=2C(=NC=C(C(=O)N[C@H](CO)C)C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC=C(C(=O)N[C@H](CO)C)C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C TUVKHJJOKKVQQH-HNNXBMFYSA-N 0.000 claims 1
- UDKLHKLQJOGEQR-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC=C(C(=O)O)C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC=C(C(=O)O)C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C UDKLHKLQJOGEQR-UHFFFAOYSA-N 0.000 claims 1
- WOVTWROWYKFHAE-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC=C(C2)OC2=NC=CC=C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C(=NC=C(C2)OC2=NC=CC=C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 WOVTWROWYKFHAE-UHFFFAOYSA-N 0.000 claims 1
- RTOLLHUTQWJUHJ-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC=C(C2)OCC2=CC=NC=C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C(=NC=C(C2)OCC2=CC=NC=C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 RTOLLHUTQWJUHJ-UHFFFAOYSA-N 0.000 claims 1
- KQWHGGROQFESOJ-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=C2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=C2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C KQWHGGROQFESOJ-UHFFFAOYSA-N 0.000 claims 1
- GSVOXRLXMKHISS-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=C2)C(=O)O)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=C2)C(=O)O)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C GSVOXRLXMKHISS-UHFFFAOYSA-N 0.000 claims 1
- MZYWWXMRVIWOLM-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=N2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=N2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 MZYWWXMRVIWOLM-UHFFFAOYSA-N 0.000 claims 1
- OJCXAZXUSBQVST-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=CC(=N2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=CC(=N2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 OJCXAZXUSBQVST-UHFFFAOYSA-N 0.000 claims 1
- SLWUKEMUEDNUNQ-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C=2C=NC(=NC2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C=2C=NC(=NC2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 SLWUKEMUEDNUNQ-UHFFFAOYSA-N 0.000 claims 1
- NFWDOQSKAKERAA-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)N2CCN(CC2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)N2CCN(CC2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 NFWDOQSKAKERAA-UHFFFAOYSA-N 0.000 claims 1
- DTNLVCAQKQJIQZ-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(N=NC2C2=CC=CC=C2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C=C(N=NC2C2=CC=CC=C2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C DTNLVCAQKQJIQZ-UHFFFAOYSA-N 0.000 claims 1
- PRMAXJDIOLIDRZ-DEOSSOPVSA-N FC1=C(C(=O)NC=2C=CC(=NC2C2=CC=CC=C2)CNC(=O)[C@H]2NC(CC2)=O)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C=CC(=NC2C2=CC=CC=C2)CNC(=O)[C@H]2NC(CC2)=O)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C PRMAXJDIOLIDRZ-DEOSSOPVSA-N 0.000 claims 1
- VANNZTMUYUEAHF-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1C=C(C=NC1C1=CC=CC=C1)C(=O)NCC=1C=NC=CC1 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1C=C(C=NC1C1=CC=CC=C1)C(=O)NCC=1C=NC=CC1 VANNZTMUYUEAHF-UHFFFAOYSA-N 0.000 claims 1
- ZNVLHMJZALQWMO-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NNC=C1)C(=O)NC=1C=C(C=NC1C1=CC=CC=C1)C(=O)N Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NNC=C1)C(=O)NC=1C=C(C=NC1C1=CC=CC=C1)C(=O)N ZNVLHMJZALQWMO-UHFFFAOYSA-N 0.000 claims 1
- MZVNKKLFPVLAEH-UHFFFAOYSA-N FC1=C(C=C(C2=NC=CC=C2)C(=C1)C(F)(F)F)C(=O)NC1=C(N=C2CCNCC2=C1)C1=CC=CC=C1 Chemical compound FC1=C(C=C(C2=NC=CC=C2)C(=C1)C(F)(F)F)C(=O)NC1=C(N=C2CCNCC2=C1)C1=CC=CC=C1 MZVNKKLFPVLAEH-UHFFFAOYSA-N 0.000 claims 1
- YCRBMKFWWJXTON-UHFFFAOYSA-N NC(=O)N1CCC2=NC(=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 Chemical compound NC(=O)N1CCC2=NC(=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 YCRBMKFWWJXTON-UHFFFAOYSA-N 0.000 claims 1
- JLBSYBPJDMIGOD-UHFFFAOYSA-N NC(CC1=CC(=C(C=N1)NC(C1=C(C=C(C(=C1)C1=NC=CC=C1)C(F)(F)F)F)=O)C1=CC=CC=C1)=O Chemical compound NC(CC1=CC(=C(C=N1)NC(C1=C(C=C(C(=C1)C1=NC=CC=C1)C(F)(F)F)F)=O)C1=CC=CC=C1)=O JLBSYBPJDMIGOD-UHFFFAOYSA-N 0.000 claims 1
- UKKIANWEKPYPBV-UHFFFAOYSA-N NC(CC1=CC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=C1)C(F)(F)F)F)=O)=O Chemical compound NC(CC1=CC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=C1)C(F)(F)F)F)=O)=O UKKIANWEKPYPBV-UHFFFAOYSA-N 0.000 claims 1
- IQZPJKBIANCQMG-UHFFFAOYSA-N NC(CC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=C1)C(F)(F)F)F)=O)=O Chemical compound NC(CC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=C1)C(F)(F)F)F)=O)=O IQZPJKBIANCQMG-UHFFFAOYSA-N 0.000 claims 1
- MUTFGNVCUSLFKO-UHFFFAOYSA-N NC(CC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O)=O Chemical compound NC(CC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O)=O MUTFGNVCUSLFKO-UHFFFAOYSA-N 0.000 claims 1
- OTFCRUXLUASLQC-UHFFFAOYSA-N NC(CC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NNC=C1)C(F)(F)F)F)=O)=O Chemical compound NC(CC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NNC=C1)C(F)(F)F)F)=O)=O OTFCRUXLUASLQC-UHFFFAOYSA-N 0.000 claims 1
- WSBRAROLRNMMAF-UHFFFAOYSA-N NC1=NC(=C(C=C1C(=O)N)NC(=O)C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)C1=CC=CC=C1 Chemical compound NC1=NC(=C(C=C1C(=O)N)NC(=O)C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)C1=CC=CC=C1 WSBRAROLRNMMAF-UHFFFAOYSA-N 0.000 claims 1
- IIVDCUPTRDMNJC-UHFFFAOYSA-N OCC(=O)NCC1=CC(=C(C=N1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O)C1=CC=CC=C1 Chemical compound OCC(=O)NCC1=CC(=C(C=N1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O)C1=CC=CC=C1 IIVDCUPTRDMNJC-UHFFFAOYSA-N 0.000 claims 1
- OOYFDNGSKVIFNT-UHFFFAOYSA-N OCC(=O)NCC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O Chemical compound OCC(=O)NCC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O OOYFDNGSKVIFNT-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/074145 WO2015143654A1 (en) | 2014-03-26 | 2014-03-26 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| CNPCT/CN2014/074145 | 2014-03-26 | ||
| PCT/US2015/021936 WO2015148344A2 (en) | 2014-03-26 | 2015-03-23 | Trka kinase inhibitors, compositions and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017512794A JP2017512794A (ja) | 2017-05-25 |
| JP2017512794A5 true JP2017512794A5 (enExample) | 2018-05-10 |
Family
ID=54193895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559249A Pending JP2017512794A (ja) | 2014-03-26 | 2015-03-23 | ＴｒｋＡキナーゼ阻害薬、その組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9815846B2 (enExample) |
| EP (1) | EP3122346B1 (enExample) |
| JP (1) | JP2017512794A (enExample) |
| KR (1) | KR20160128420A (enExample) |
| CN (1) | CN106794161A (enExample) |
| AU (1) | AU2015236428B2 (enExample) |
| BR (1) | BR112016022069A2 (enExample) |
| CA (1) | CA2943858A1 (enExample) |
| MX (1) | MX2016012480A (enExample) |
| RU (1) | RU2672583C2 (enExample) |
| WO (2) | WO2015143654A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX385843B (es) | 2014-09-12 | 2025-03-18 | Antibiotx Aps | Uso antibacteriano de salicilanilidas halogenadas. |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| GB201604484D0 (en) | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
| JP6965083B2 (ja) * | 2017-10-04 | 2021-11-10 | 公益財団法人微生物化学研究会 | 化合物、及び発光化合物 |
| CN108794414B (zh) * | 2018-06-22 | 2021-01-01 | 浙江大学 | 芳酰胺基取代的均三嗪类化合物及制备和应用 |
| CN108997224B (zh) * | 2018-08-28 | 2023-04-28 | 韶远科技（上海)有限公司 | 一种2-氯-5-氰基含氮六元杂环化合物的制备方法 |
| MA54546A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
| MA54550A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| AU2019401495B2 (en) | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CN114391012B (zh) | 2019-08-02 | 2025-10-31 | 美国安进公司 | 作为kif18a抑制剂的吡啶衍生物 |
| ES3051918T3 (en) | 2019-08-02 | 2025-12-30 | Amgen Inc | Kif18a inhibitors |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4153223A1 (en) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
| AR122141A1 (es) | 2020-05-28 | 2022-08-17 | Lilly Co Eli | Inhibidor de trka |
| WO2022090101A1 (en) | 2020-10-26 | 2022-05-05 | Boehringer Ingelheim International Gmbh | Process for synthesis of 2,4-dichloro-5-aminopyrimidine |
| EP4402137A4 (en) * | 2021-09-14 | 2025-10-15 | Univ Vanderbilt | PHENYL RING COMPOUNDS AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU5 AND METHODS OF PRODUCTION AND USE THEREOF |
| CN113880724A (zh) * | 2021-12-06 | 2022-01-04 | 南京桦冠生物技术有限公司 | 一种3-(2-氨基苯基)-2-丙烯酸酯的制备方法 |
| KR20230153959A (ko) * | 2022-04-29 | 2023-11-07 | 제일약품주식회사 | 신규한 pim 키나아제 억제 화합물 및 이의 용도 |
| WO2024233922A2 (en) * | 2023-05-10 | 2024-11-14 | Texas Tech University System | Pyridine-piperazine-based scaffolds as highly potent and selective neurolysin activators |
| CN121464124A (zh) * | 2023-05-30 | 2026-02-03 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| CN116751115A (zh) * | 2023-07-03 | 2023-09-15 | 苏州诚和医药化学有限公司 | 一种间甲氧基氯苄的制备方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4638014A (en) * | 1985-08-26 | 1987-01-20 | Research Corporation | Anticonvulsant method and formulations |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| EP1208085B1 (en) * | 1999-08-04 | 2007-12-05 | Icagen, Inc. | Benzanilides as potassium channel openers |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| CN102746399B (zh) | 2002-12-24 | 2016-03-02 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| AU2004236240C1 (en) | 2003-05-01 | 2010-11-04 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole compounds useful as kinase inhibitors |
| CN1849138B (zh) | 2003-07-15 | 2011-11-30 | 安姆根有限公司 | 作为选择性ngf途径抑制剂的人抗ngf中和抗体 |
| JP2007506741A (ja) | 2003-09-23 | 2007-03-22 | メルク エンド カムパニー インコーポレーテッド | 向代謝性グルタミン酸受容体のピラゾール系調節剤 |
| US20050143384A1 (en) | 2003-10-30 | 2005-06-30 | Eric Sartori | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| ATE517885T1 (de) | 2004-04-30 | 2011-08-15 | Bayer Healthcare Llc | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
| EP1853602B1 (en) | 2005-02-16 | 2010-07-14 | AstraZeneca AB | Chemical compounds |
| EP1853610A1 (en) | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| CN101208093A (zh) | 2005-04-27 | 2008-06-25 | 阿斯利康(瑞典)有限公司 | 吡唑-嘧啶衍生物在治疗疼痛中的用途 |
| BRPI0610184A2 (pt) | 2005-05-16 | 2012-09-25 | Astrazeneca Ab | composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
| EP1910369A1 (en) | 2005-07-29 | 2008-04-16 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| CA2618370A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| CN101287707A (zh) | 2005-10-13 | 2008-10-15 | 德福根有限公司 | 激酶抑制剂 |
| JP2009519208A (ja) | 2005-12-15 | 2009-05-14 | 塩野義製薬株式会社 | アミド誘導体を含有する医薬組成物 |
| JP5153773B2 (ja) | 2006-07-07 | 2013-02-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フェニル置換ヘテロアリール誘導体及び抗癌剤としてのその使用 |
| JP2010508315A (ja) | 2006-10-30 | 2010-03-18 | ノバルティス アーゲー | 抗炎症剤としてのヘテロ環式化合物 |
| ES2534573T3 (es) | 2007-04-06 | 2015-04-24 | Neurocrine Biosciences, Inc. | Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos |
| JP5383483B2 (ja) * | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
| CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| JP2010531850A (ja) | 2007-07-02 | 2010-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
| CL2008001943A1 (es) * | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
| NZ585237A (en) | 2007-10-09 | 2012-03-30 | Merck Patent Gmbh | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators |
| JPWO2009131173A1 (ja) * | 2008-04-23 | 2011-08-18 | 協和発酵キリン株式会社 | ２−アミノキナゾリン誘導体 |
| EP2272832A4 (en) * | 2008-04-28 | 2011-09-07 | Asahi Kasei Pharma Corp | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF |
| DK2350075T3 (da) | 2008-09-22 | 2014-05-26 | Array Biopharma Inc | Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer |
| AU2009300318A1 (en) * | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US8703962B2 (en) | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
| US9040508B2 (en) | 2008-12-08 | 2015-05-26 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
| JP2012522013A (ja) | 2009-03-27 | 2012-09-20 | ザ ユーエービー リサーチ ファウンデーション | 調節ｉｒｅｓ媒介翻訳 |
| JP2013522192A (ja) * | 2010-03-11 | 2013-06-13 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎の処置のための化合物 |
| WO2011130595A2 (en) * | 2010-04-15 | 2011-10-20 | Sirtris Pharmaceuticals, Inc. | Sirtuin activators and activation assays |
| MX2012015105A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Inhibidores de cinasa de regulacion mediante señal de apoptosis. |
| EP2611785B1 (de) | 2010-09-01 | 2014-06-04 | Bayer Intellectual Property GmbH | N-(tetrazol-5-yl)- und n-(triazol-5-yl)arylcarbonsäureamide und ihre verwendung als herbizide |
| WO2012100223A1 (en) | 2011-01-21 | 2012-07-26 | John Irwin | Synthetic lethal targeting of glucose transport |
| AR085318A1 (es) | 2011-02-09 | 2013-09-25 | Syngenta Participations Ag | Derivados de triazol que tienen actividad insecticida |
| PE20141050A1 (es) * | 2011-04-05 | 2014-08-30 | Pfizer Ltd | Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina |
| MY173181A (en) | 2011-05-13 | 2020-01-02 | Array Biopharma Inc | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors |
| PL2714668T3 (pl) | 2011-05-23 | 2017-06-30 | Merck Patent Gmbh | Pochodne tiazolowe |
| CN102796103A (zh) | 2011-05-23 | 2012-11-28 | 南京英派药业有限公司 | 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用 |
| KR20130077390A (ko) * | 2011-12-29 | 2013-07-09 | 제이더블유중외제약 주식회사 | 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체 |
| CN104334529B (zh) * | 2012-05-15 | 2017-03-15 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物 |
| EP2858501A4 (en) | 2012-05-22 | 2015-12-09 | Merck Sharp & Dohme | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHOD THEREFOR |
| AR091586A1 (es) * | 2012-06-28 | 2015-02-11 | Fujifilm Corp | Derivado de amida o su sal como inhibidor de la produccion de colageno |
| EP2689779A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| JP5840324B2 (ja) * | 2013-04-15 | 2016-01-06 | 株式会社レナサイエンス | Ｐａｉ−１阻害剤の新規用途 |
-
2014
- 2014-03-26 WO PCT/CN2014/074145 patent/WO2015143654A1/en not_active Ceased
-
2015
- 2015-03-23 KR KR1020167029501A patent/KR20160128420A/ko not_active Withdrawn
- 2015-03-23 CN CN201580029747.2A patent/CN106794161A/zh active Pending
- 2015-03-23 EP EP15769367.2A patent/EP3122346B1/en not_active Not-in-force
- 2015-03-23 JP JP2016559249A patent/JP2017512794A/ja active Pending
- 2015-03-23 WO PCT/US2015/021936 patent/WO2015148344A2/en not_active Ceased
- 2015-03-23 RU RU2016141646A patent/RU2672583C2/ru not_active IP Right Cessation
- 2015-03-23 BR BR112016022069A patent/BR112016022069A2/pt not_active Application Discontinuation
- 2015-03-23 MX MX2016012480A patent/MX2016012480A/es unknown
- 2015-03-23 CA CA2943858A patent/CA2943858A1/en not_active Abandoned
- 2015-03-23 AU AU2015236428A patent/AU2015236428B2/en not_active Ceased
- 2015-03-23 US US15/128,689 patent/US9815846B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512794A5 (enExample) | ||
| RU2016141646A (ru) | Ингибиторы trka киназы, основанные на них композиции и способы | |
| JP7216682B2 (ja) | Ｕｓｐ３０阻害剤としての１－シアノ－ピロリジン化合物 | |
| JP5809267B2 (ja) | 血漿カリクレイン阻害剤としてのｎ−（（６−アミノ−ピリジン−３−イル）メチル）−ヘテロアリール−カルボキサミド類 | |
| US8314094B2 (en) | Benzoxazinone derivative | |
| JP2017508766A5 (enExample) | ||
| ES2708211T3 (es) | 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas | |
| JP7517992B2 (ja) | 化合物及びその使用 | |
| IL282840B1 (en) | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha | |
| US20080113967A1 (en) | Enzyme modulators and treatments | |
| JP2017512786A5 (enExample) | ||
| JP2017531679A (ja) | キナーゼ阻害剤として有用なインドールカルボキシアミド | |
| JP2016523911A5 (enExample) | ||
| MX2012008280A (es) | Compuestos y metodos. | |
| KR20150135794A (ko) | 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도 | |
| WO2020198026A1 (en) | Compounds and uses thereof | |
| CN103096718A (zh) | 可溶性鸟苷酸环化酶活化剂 | |
| KR20070007103A (ko) | 벤즈아미드 유도체 및 이의 글루코키나아제 활성화제로서의용도 | |
| AU2005267884A1 (en) | Potassium channel inhibitors | |
| CA2656715A1 (en) | Compounds and compositions as itpkb inhibitors | |
| RU2015111133A (ru) | Ингибиторы тирозинкиназы брутона | |
| AU2021322052A1 (en) | 2-(4-((5-(benzo[b]thiophen-3-yl)-1H-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy | |
| JP2017523223A5 (enExample) | ||
| JP2014513122A5 (enExample) | ||
| JP2019530708A5 (enExample) |